

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Charles Rudin named cancer center director at MSK
- How City of Hope is turning microbiome science into better cancer care
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use
- What are you reading in 2024?
















